Lv21
120 积分 2025-05-13 加入
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)
2个月前
已完结
Fingolimod in multiple sclerosis: insights into drug survival and discontinuation factors
2个月前
已完结
Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab
2个月前
已完结
Long-term tolvaptan therapy in a case of very early-onset polycystic kidney disease
2个月前
已完结
Trends in the use of sodium-glucose cotransporter-2 inhibitors and characteristics of adverse event reporting in patients with heart failure in Japan: reports from the medical administration database and the adverse event reporting database
2个月前
已完结
皖公网安备34019202002308
